CLAIMS:

1. An isolated antibody, or an antigen-binding portion thereof, that binds to LY75, said antibody or portion comprising:

a) a heavy chain variable region comprising:

i) a first vhCDR comprising SEQ ID NO: 5;

ii) a second vhCDR comprising SEQ ID NO: 6; and

iii) a third vhCDR comprising SEQ ID NO: 7; and

b) a light chain variable region comprising:

i) a first vlCDR comprising SEQ ID NO: 8;

ii) a second vlCDR comprising SEQ ID NO: 9; and

iii) a third vlCDR comprising SEQ ID NO: 10.

2. The isolated antibody or an antigen-binding portion thereof according to claim 1, comprising a heavy chain variable region having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 1 and a light chain variable region having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 2.

3. The isolated antibody or an antigen-binding portion thereof according to claim 1 or claim 2, further comprising a covalently-attached moiety.

4. The isolated antibody or an antigen-binding portion thereof according to claim 3, wherein said moiety is a drug.

5. The isolated antibody or an antigen-binding portion thereof according to claim 4, wherein said drug is selected from the group consisting of a maytansinoid, a dolastatin, a hemiasterlin, an auristatin, a trichothecene, a calicheamicin, CC1065 and derivatives thereof.

6. The isolated antibody or an antigen-binding portion thereof according to claim 5, wherein said drug is a maytansinoid selected from the group consisting of maytansinoid DM4 and maytansinoid DM1.

7. A pharmaceutical composition comprising an antibody or antigen binding portion thereof according to any one of the previous claims, together with one or more pharmaceutically-acceptable diluents, excipients or carriers.

8. A nucleic acid encoding a heavy chain of the antibody or an antigen-binding portion thereof of any one of claims to 1 to 6.

9. A nucleic acid encoding a light chain of the antibody or an antigen-binding portion thereof of any one of claims 1 to 6.

10. An expression vector comprising the nucleic acid of claim 8 operably linked to one or more regulatory elements and/or the nucleic acid of claim 9 operably linked to one or more regulatory elements.

11. A host cell comprising:
(i) an expression vector comprising the nucleic acid of claim 8 operably linked to one or more regulatory elements and the nucleic acid of claim 9 operably linked to one or more regulatory elements; or
(ii) a first expression vector comprising the nucleic acid of claim 8 operably linked to one or more regulatory elements and a second expression vector comprising the nucleic acid of claim 9 operably linked to one or more regulatory elements.

12. A method of making an antibody or an antigen-binding portion thereof, comprising culturing a host cell according to claim 11 under conditions where the antibody or an antigen-binding portion thereof is expressed and optionally isolating the antibody or an antigen-binding portion thereof.

13. The antibody or an antigen-binding portion thereof according to any one of claims 1 to 6 for use in the treatment of cancer, wherein the cells of the cancer express LY75, and wherein the antibody or antigen-binding portion comprises a covalently attached drug conjugate.

14. The antibody or antigen binding portion thereof for use according to claim 13, wherein the antibody or antigen-binding portion thereof is internalized by a cell expressing LY75.

15. The antibody or antigen binding portion thereof for use according to claim 13 or claim 14, wherein the covalently attached drug conjugate is a maytansinoid, preferably maytansinoid DM4.

16. The antibody or antigen binding portion thereof for use according to any one of claims 13 to 15 wherein said cancer is selected from the group consisting of pancreatic cancer, ovarian cancer, breast cancer, colorectal cancer, esophageal cancer, skin cancer, thyroid cancer, lung cancer, kidney cancer, liver cancer, head and neck cancer, bladder cancer, gastric cancer, leukaemia, preferably acute myeloid leukaemia or chronic lymphocytic leukaemia, myeloma, preferably multiple myeloma and lymphoma, preferably diffuse large B-cell lymphoma (DLBCL), B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT), T-Cell/Histiocyte-Rich B-Cell Lymphoma, Burkitt’s Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, T Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma and AngioImmunoblastic T-Cell Lymphoma.

17. The antibody or antigen binding portion thereof for use according to claim 16, wherein the cancer is selected from the group consisting of bladder cancer, pancreatic cancer, triple-negative breast cancer and DLBCL.

18. Use of the antibody or an antigen-binding portion thereof according to any one of claims 1 to 6 in the manufacture of a medicament for the treatment of cancer, wherein the cells of the cancer express LY75, and wherein the antibody or antigen-binding portion comprises a covalently attached drug conjugate.

19. The use according to claim 18, wherein the antibody or antigen-binding portion thereof is internalized by a cell expressing LY75.

20. The use according to claim 18 or claim 19, wherein the covalently attached drug conjugate is a maytansinoid, preferably maytansinoid DM4.

21. The use according to any one of claims 18 to 20 wherein said cancer is selected from the group consisting of pancreatic cancer, ovarian cancer, breast cancer, colorectal cancer, esophageal cancer, skin cancer, thyroid cancer, lung cancer, kidney cancer, liver cancer, head and neck cancer, bladder cancer, gastric cancer, leukaemia, preferably acute myeloid leukaemia or chronic lymphocytic leukaemia, myeloma, preferably multiple myeloma and lymphoma, preferably diffuse large B-cell lymphoma (DLBCL), B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT), T-Cell/Histiocyte-Rich B-Cell Lymphoma, Burkitt's Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, T Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma and AngioImmunoblastic T-Cell Lymphoma.

22. The use according to claim 21, wherein the cancer is selected from the group consisting of bladder cancer, pancreatic cancer, triple-negative breast cancer and DLBCL.

23. An antibody, or an antigen-binding portion thereof, according to any one of claims 4 to 6 for use in therapy or for use as a medicament.